Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 2 3Phase 1/2 2

Status

Completed 3Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 3

Conditions

Breast Neoplasms 1278Carcinoma, Non-Small-Cell Lung 927Prostatic Neoplasms 729Neoplasms 633Multiple Myeloma 554Lymphoma 540Colorectal Neoplasms 530Lung Neoplasms 515Leukemia 498Leukemia, Myeloid, Acute 474Neoplasm Metastasis 471Melanoma 426Lymphoma, Non-Hodgkin 420Ovarian Neoplasms 417Leukemia, Lymphocytic, Chronic, B-Cell 386Pancreatic Neoplasms 373Recurrence 338Precursor Cell Lymphoblastic Leukemia-Lymphoma 329Head and Neck Neoplasms 307Lymphoma, Large B-Cell, Diffuse 295Glioblastoma 294Myelodysplastic Syndromes 288Lymphoma, Follicular 287Brain Neoplasms 287Stomach Neoplasms 282Carcinoma, Renal Cell 268Carcinoma, Hepatocellular 262Hodgkin Disease 261Rectal Neoplasms 256Sarcoma 250

Interventions

Ramucirumab 2etirinotecan pegol 1Paclitaxel 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Completed × Malignant Solid Tumor × Clear all
NCT01515306 2022-03-08

A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors

Eli Lilly and Company

Phase 2 Completed
48 enrolled 17 charts
Other solid neoplasm

Malignant Solid Tumor

NCT01457118 2021-07-12

An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies

Nektar Therapeutics

Phase 2 Completed
27 enrolled 18 charts
Other solid neoplasm

Malignant Solid Tumor

NCT01567163 2014-10-16

A Study of Ramucirumab and Docetaxel in Participants With Solid Tumors

Eli Lilly and Company

Phase 2 Completed
22 enrolled 15 charts
Other solid neoplasm

Malignant Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡